Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
NCT00171236Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2001
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluvastatin in heterozygous familial hypercholesterolemia (HeFH), sponsored by Novartis. Primary endpoint: Low-Density Lipoprotein Cholesterol at 2 years. Started Oct 2001; status: completed.
02
Drugs
fluvastatin
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00171236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171236.